Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 391 to 400 of 851 total matches.
Penicillin Allergy
The Medical Letter on Drugs and Therapeutics • Aug 12, 1988 (Issue 772)
FOR
ONLINE USERS
PENICILLIN ALLERGY
A penicillin is the drug of choice for treatment of many infections ...
A penicillin is the drug of choice for treatment of many infections, but allergic reactions to these drugs occur frequently and, rarely, can be fatal. From 5% to 20% of patients have a history of a rash or some other reaction while taking a penicillin, but maculopapular rashes with ampicillin or amoxicillin, especially in children with infectious mononucleosis, are probably not allergic.
H. Influenzae Vaccine For Infants
The Medical Letter on Drugs and Therapeutics • Jan 25, 1991 (Issue 836)
. influenzae infection (GR Siber
et al, N Engl J Med, 323:1387, Nov 15, 1990). Despite the availability ...
The US Food and Drug Administration (FDA) recently approved HibTITER (Lederle-Praxis) and PedvaxHIB (Merck), two new Haemophilus influenzae type b conjugate vaccines, for use in infants as part of their primary immunization schedule.
Testosterone Patches for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 24, 1996 (Issue 975)
are also low in many HIV-infected patients; the mechanism is not clear (L Poretsky et al, Metabolism, 44 ...
Men with primary or secondary hypogonadism require lifelong androgen replacement to prevent osteoporosis and maintain normal muscle mass, erythropoiesis and sexual function (AM Matsumoto, Endocrinol Metab Clin North Am, 23:857, 1994). Until recently, the standard treatment for male hypogonadism has been an intramuscular injection of a long-acting testosterone ester every two to three weeks, which leads to serum testosterone concentrations that are high for a few days, normal for a few days more, and then may be subnormal until the next dose. Two transdermal preparations of testosterone...
Peginterferon Alfa-2a (Pegasys) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
) infections not previously treated with interferon alpha. The
standard of care for treatment of most patients ...
The FDA has approved recombinant interferon alfa-2a conjugated to polyethylene glycol (Pegasys - Roche) alone or with oral ribavirin (Copegus - Roche) for treatment of adults with chronic hepatitis C virus (HCV) infections not previously treated with interferon alpha. The standard of care for treatment of most patients with hepatitis C has been once-weekly injections of peginterferon alfa-2b (PEG-Intron -Schering) plus oral ribavirin (Rebetol - Schering) (Medical Letter 2001; 43:54).
Herpes Zoster Vaccine (Zostavax)
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006 (Issue 1243)
primary infection
(varicella), VZV persists in a latent form in sensory
ganglia. VZV-specific cell ...
A live attenuated varicella-zoster vaccine (Zostavax - Merck) has been approved by the FDA for prevention of herpes zoster (HZ; zoster; shingles) in persons ≥60 years old. Each dose of Zostavax contains about 14 times as much varicella-zoster virus (VZV) as Varivax, which has been used in the US since 1995 to vaccinate against varicella (chicken pox).
A New Rotavirus Vaccine
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008 (Issue 1293)
-2003. J Infect Dis 2007; 195:1117.
The Medical Letter publications are protected ...
Rotarix, an oral live-attenuated rotavirus vaccine, has been approved by the FDA for prevention of rotavirus gastroenteritis in infants and children. Rota-Shield was withdrawn from the market because of an association with intussusception. RotaTeq, an oral live, human-bovine reassortant rotavirus vaccine, is recommended by the American Academy of Pediatrics as a routine immunization.
A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2013 (Issue 1412)
of urinary tract infection and toxic shock
syndrome; requires fitting by healthcare
professional
Condom ...
The FDA recently approved Skyla (Bayer), the first new
intrauterine device (IUD) in the US in 12 years. It
releases levonorgestrel, a synthetic progestin, over a
period of 3 years. A table summarizing contraceptive
methods available in the US appears on page 22.
Remdesivir (Veklury) for COVID-19
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020 (Issue 1612)
and evidence of lower respiratory tract infection were randomized to receive remdesivir or placebo for up to 10 ...
The FDA has approved the antiviral drug remdesivir
(Veklury – Gilead) for IV treatment of COVID-19 in
hospitalized patients who are ≥12 years old and weigh
≥40 kg. Hospitalized children who are <12 years old
or weigh <40 kg can receive remdesivir through an
Emergency Use Authorization (EUA). Remdesivir is
the first drug to be approved in the US for treatment
of COVID-19.
Sarilumab (Kevzara) for Polymyalgia Rheumatica
The Medical Letter on Drugs and Therapeutics • May 13, 2024 (Issue 1702)
reactions and serious infections can occur.
Dosage: 200 mg SC q2 weeks.
Cost: One year of treatment costs ...
The FDA has approved the interleukin (IL)-6 inhibitor
sarilumab (Kevzara – Sanofi/Regeneron) for treatment
of polymyalgia rheumatica (PMR) in adults who
had an inadequate response to corticosteroids or
cannot tolerate a corticosteroid taper. Sarilumab is
the first biologic drug to be approved for treatment
of PMR; it was previously approved for treatment of
rheumatoid arthritis.
Med Lett Drugs Ther. 2024 May 13;66(1702):77-8 doi:10.58347/tml.2024.1702c | Show Introduction Hide Introduction
A New Conjugate Meningococcal Vaccine (Menveo)
The Medical Letter on Drugs and Therapeutics • Jul 26, 2010 (Issue 1343)
of meningococcal disease: current use
of polysaccharide and conjugate vaccines. Clin Infect Dis
2010; 50: S45.
3 ...
The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for
protection against disease caused by Neisseria meningitidis in people 11-55 years old.